William Guyer Sells 20,000 Shares of Corcept Therapeutics (NASDAQ:CORT) Stock

Corcept Therapeutics Incorporated (NASDAQ:CORT) insider William Guyer sold 20,000 shares of the stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $40.87, for a total value of $817,400.00. Following the completion of the transaction, the insider owned 1,235 shares of the company’s stock, valued at $50,474.45. This represents a 94.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

William Guyer also recently made the following trade(s):

• On Tuesday, January 6th, William Guyer sold 20,000 shares of Corcept Therapeutics stock. The stock was sold at an average price of $35.18, for a total value of $703,600.00.
• On Tuesday, December 2nd, William Guyer sold 20,000 shares of Corcept Therapeutics stock. The shares were sold at an average price of $80.08, for a total transaction of $1,601,600.00.
• On Tuesday, November 25th, William Guyer sold 4,500 shares of Corcept Therapeutics stock. The stock was sold at an average price of $80.90, for a total transaction of $364,050.00.

Corcept Therapeutics Trading Up 6.4%

CORT opened at $40.83 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.14 and a quick ratio of 3.07. Corcept Therapeutics Incorporated has a fifty-two week low of $32.99 and a fifty-two week high of $117.33. The company’s 50 day moving average price is $58.17 and its two-hundred day moving average price is $69.08. The firm has a market capitalization of $4.29 billion, a price-to-earnings ratio of 46.40 and a beta of 0.25.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.16 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.02). Corcept Therapeutics had a return on equity of 15.99% and a net margin of 14.19%.The business had revenue of $207.64 million for the quarter, compared to analyst estimates of $223.78 million. During the same quarter last year, the firm posted $0.41 EPS. Corcept Therapeutics’s revenue for the quarter was up 13.8% on a year-over-year basis. As a group, research analysts predict that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current year.

Hedge Funds Weigh In On Corcept Therapeutics

Several institutional investors have recently made changes to their positions in the stock. AQR Capital Management LLC increased its position in Corcept Therapeutics by 546.9% in the 3rd quarter. AQR Capital Management LLC now owns 1,507,209 shares of the biotechnology company’s stock valued at $125,264,000 after buying an additional 1,274,215 shares in the last quarter. Norges Bank bought a new stake in shares of Corcept Therapeutics during the second quarter valued at approximately $72,048,000. TD Asset Management Inc raised its position in shares of Corcept Therapeutics by 16.6% during the third quarter. TD Asset Management Inc now owns 956,136 shares of the biotechnology company’s stock worth $79,464,000 after purchasing an additional 136,254 shares during the period. JPMorgan Chase & Co. raised its position in shares of Corcept Therapeutics by 223.4% during the third quarter. JPMorgan Chase & Co. now owns 849,864 shares of the biotechnology company’s stock worth $70,632,000 after purchasing an additional 587,053 shares during the period. Finally, Epoch Investment Partners Inc. lifted its holdings in shares of Corcept Therapeutics by 10.7% in the 3rd quarter. Epoch Investment Partners Inc. now owns 847,104 shares of the biotechnology company’s stock worth $70,403,000 after purchasing an additional 81,700 shares in the last quarter. Institutional investors and hedge funds own 93.61% of the company’s stock.

Trending Headlines about Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Analyst support — several firms have recently raised price targets and maintained buy views (HC Wainwright, Canaccord among others), which can lift sentiment and buying interest for CORT.
• Positive Sentiment: Longer‑term performance story — coverage highlighting that investors are up materially over a multi‑year period helps justify accumulation for some holders and frames today’s move as part of a broader recovery narrative. Despite lower earnings than three years ago, Corcept Therapeutics (NASDAQ:CORT) investors are up 71% since then
• Neutral Sentiment: Short‑interest data appears non‑informative — the reported short interest shows 0 shares (likely a data/reporting artifact), so short pressure is not a meaningful current driver.
• Neutral Sentiment: Recent fundamentals — the company’s last reported quarter missed EPS and revenue estimates (Nov 4 release), which remains in the background for investors weighing valuation vs. growth prospects.
• Negative Sentiment: Multiple securities‑law investigations — several plaintiff firms (Kaplan Fox & Kilsheimer, Bernstein Liebhard, Schall Law Firm, DJS Law Group) have announced probes into Corcept, alleging possible disclosure or misstatement issues; that increases litigation risk, news flow uncertainty, and potential future liabilities. CORCEPT THERAPEUTICS Investors Are Encouraged to Contact Kaplan Fox & Kilsheimer LLP Bernstein Liebhard investigation alert Schall Law Firm investigation DJS Law Group investigation
• Negative Sentiment: Insider selling — director William Guyer sold 20,000 shares at about $40.87 (filed with the SEC), substantially reducing his stake; large insider sales often spur caution among investors and can pressure the stock. SEC filing: insider sale

Wall Street Analyst Weigh In

CORT has been the topic of several analyst reports. Wolfe Research cut Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 target price on the stock. in a report on Wednesday, December 31st. Canaccord Genuity Group increased their price objective on shares of Corcept Therapeutics from $99.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, January 23rd. Wall Street Zen lowered shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, October 18th. Zacks Research cut shares of Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 13th. Finally, Truist Financial set a $50.00 price objective on Corcept Therapeutics in a research report on Wednesday, December 31st. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $83.50.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.